| ||
| ASCO roundup: Fresh progress of Merck, Pfizer cancer drugs FierceBiotech (You can find fresh data on approved cancer drugs over at FiercePharma this morning). Pfizer got a boost from an enthusiastic response to the latest data on crizotinib, its lung cancer drug aimed at a small percentage of patients with ALK-positive ... See all stories on this topic » | ||
| Addition of cetuximab to oxaliplatin-based chemotherapy in advanced colorectal ... ecancermedicalscience by ecancer reporter Clare Sansom Many tumours contain mutations in the epidermal growth factor receptor (EGFR), a gene that encodes a tyrosine kinase that acts as a powerful oncogene and that is now a very important cancer drug target. In lung cancer ... See all stories on this topic » | ||
| Chicago-area Businesses Support Lung Cancer Research TribLocal Despite the monumental impact of lung cancer in the US, a stigma associated with the disease has prevented businesses from supporting research that would have an impact on improving lung cancer survival rates, ensure a higher quality of life for lung ... See all stories on this topic » | ||
| ||
| Synta Announces Presentation of Additional Ganetespib Results at ASCO Business Wire (press release) "The results reported Saturday demonstrated compelling proof of clinical activity in lung cancer patients with ALK+ tumors. The results reported today show that ganetespib has broad potential, with activity seen in breast cancer, melanoma, ... See all stories on this topic » | ||
| Fellowship fuels cancer fight Delmarva Now Ann Tyndall, left, executive director of the Cancer Support Community, looks on as Alfreda Johnson of Salisbury, a breast cancer survivor, finishes pinning on her sister Ruth's lung cancer survivor pin. Ruth P. Johnson is of Princess Anne. ... See all stories on this topic » | ||
| New drug treatment for skin cancer 'as big a breakthrough as chemotherapy' Scottish Daily Record Both could extend the lives of people with the deadliest form of skin cancer, malignant melanoma. Experts believe they will also work on prostate, liver, lung and head cancers. The results of the ground-breaking trials were presented to 2000 of the ... See all stories on this topic » | ||
| Astellas Announces New Study Results Showing Increased Survival Rate for ... PR Newswire (press release) Agensys is progressing a pipeline of both naked and antibody-drug conjugated (ADC) therapeutic antibodies, directed at a variety of cancer indications, including those of the prostate, kidney, pancreas, ovary, bladder, lung, colon, breast and skin. ... See all stories on this topic » | ||
| Impax Labs Gets FDA Warning Forbes Elsewhere in pharma news, two Pfizer ( PFE - news - people ) cancer drugs are showing promising results. According to data presented Sunday, the company's advanced lung cancer drug crizotinib appears to double survival over standard drugs against ... See all stories on this topic » | ||
| Gilda's Club Celebrates National Cancer Survivors Day Patch.com For the past two-and-a-half years, he has been care partner to his wife, who has been diagnosed with stage four lung cancer. Why "care partner?," he asked the audience rhetorically. "Because the person you are caring for gives you information," he said ... See all stories on this topic » | ||
| 11 Stocks to Watch: Exco, Barrick Gold TheStreet.com Pfizer's(PFE) advanced lung cancer drug crizotinib may double survival over standard drugs against tumors with a certain genetic mutation, cancer specialists said at a conference Sunday, according to The Associated Press. Shares of Pfizer were down ... See all stories on this topic » | ||
| Combination antibody therapy shows promise in metastatic melanoma treatment HealthCanal.com A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase I clinical trial led by Dana-Farber Cancer ... See all stories on this topic » | ||
| Two Clinical Studies Evaluating Benefits of ABRAXANE® Combinations in Patients ... Business Wire (press release) Median PFS for patients in the ABRAXANE arm was estimated to be 6.6 months and the median overall survival (OS) was estimated to be 13.9 months. The 12-month survival rate was 58.1% (95% CI: 45.9%-73.6%). The confirmed response rate was 33.3%. ... See all stories on this topic » | ||
| Symphogen Presents Results from the First Clinical Trial with Sym004 at ASCO Business Wire (press release) A total of 20 patients with refractory or recurrent advanced late stage solid tumors without available therapeutic options (12 colon, 2 rectal, 2 lung, 3 pancreatic, 1 spinal chordoma), received weekly doses of Sym004. The main eligibility criteria ... See all stories on this topic » | ||
| Stock Futures Lower on Jobs Report Aftermath. Stocks to Watch: AAPL, ARMH, CAT ... TradersHuddle.com Pfizer (NYSE:PFE), the world's largest pharmaceutical company, was edging 0.14% lower to $20.81, as according to a company sponsored early phase study Crizotinib, a much anticipated drug for advanced lung cancer, appears to double survival over ... See all stories on this topic » | ||
| Phase II Study Evaluating Clinical Benefits of ABRAXANE® Plus Gemcitabine and ... Business Wire (press release) ABRAXANE is currently in various stages of investigation for the treatment of the following cancers: expanded applications for metastatic breast, non-small cell lung, malignant melanoma, pancreatic and gastric. ABRAXANE ® for Injectable Suspension ... See all stories on this topic » | ||
| Skin cancer preventable, treatable early SalemNews.net There are more than 3.5 million cases diagnosed annually, according to the Skin Cancer Foundation. According to the foundation, each year there are more new cases of skin cancer than the combined incidence of cancers of the breast, prostate, lung and ... See all stories on this topic » | ||
| BDCM, SSOL, GNTA and OXGN are the Daily Market Movers for June 6th from ... Emailwire (press release) The company's product ZYBRESTAT, is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase Ib and II clinical trials for other solid tumors, including non-small cell lung cancer, ... See all stories on this topic » | ||
| Exelixis' Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity ... Business Wire (press release) Unlike most clinical trials in CRPC, which is a bone-predominant malignancy, all 171 patients enrolled in this trial had measurable soft tissue disease per mRECIST, of which 37% had evidence of disease in liver or lung. ... See all stories on this topic » |
| ||
| Cancer News in Context: Effective Ovarian Cancer Screening Still ... By Graham Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305( 22):2295-303. 2. Nyante SJ, Black A, Kreimer AR, Duggan MA, Carreon JD, ... Cancer News in Context - http://www.cancernewsincontext.org/ |
| ||
| Study: Pfizer lung cancer pill may double survival - trentonian.com The latest Trenton Local News, New Jersey, Bucks County, Pa., Breaking News, Sports News, Watch Video & Streaming, Entertainment, Jobs, Real Estate, ... www.trentonian.com/.../doc4debcb8e9e5a6243301431.txt | ||
| Pfizer Inc. Lung Cancer Pill May Double Survival - News, Search ... An experimental drug called crizotinib sharply increases survival in lung cancer patients with a specific genetic mutation, researchers said Sunday. ... www.biospace.com/news_story.aspx?StoryID=222936&full... | ||
| Study: Pfizer lung cancer pill may double survival - Worldnews.com LINDA A. JOHNSON AP Business Writer= TRENTON, New Jersey (AP) — New research shows a promising drug for advanced lung tumors with a certain genetic mutation ... article.wn.com/.../Study_Pfizer_lung_cancer_pill_may_double... |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment